 Healthcare investors can look past the development risk. Global Blood Therapeutics NASDAQ: GBT crushed analyst estimates when it reported its first-quarter results on May 6. In its first full quarter on the market, Global Bloods sickle cell disease drug Oxbryta posted 14.1 million in net sales. 